BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for CNS and Metabolic Research

Executive Summary: BIIE 0246 is a high-affinity, selective antagonist of the neuropeptide Y Y2 receptor (Y2R), with IC₅₀ values as low as 3.3 nM and Ki values between 8–15 nM under in vitro conditions (APExBIO). It reliably blocks Y2R-mediated presynaptic inhibition and has been shown to suppress NPY-induced synaptic effects in rat hippocampal slices. In vivo, BIIE 0246 completely blocks PYY3-36-induced colon contraction and attenuates post-prandial satiety and anxiolytic-like behavior in validated rodent models. The compound is extensively referenced for mechanistic studies of the adipose-neural axis and neurocardiac regulation (Fan et al. 2024). Storage and solubility characteristics are well-defined for experimental reproducibility.

Biological Rationale

The neuropeptide Y (NPY) system is a central modulator of neuronal and metabolic function. The Y2 receptor (Y2R) is a G-protein-coupled receptor distributed in the central and peripheral nervous systems (Fan et al. 2024). Y2R regulates presynaptic neurotransmitter release, feeding behavior, anxiety, and gastrointestinal motility. Dysfunction of NPY signaling is implicated in metabolic, neuropsychiatric, and cardiac disorders. Recent studies highlight the role of the adipose-neural axis—including NPY—in epicardial adipose tissue-related arrhythmias. In this context, Y2R provides a precise pharmacological target for dissecting NPY-driven pathways in vivo and in vitro (see this roadmap for translational research—this article expands on translational models by specifying compound and workflow parameters not addressed in previous reviews).

Mechanism of Action of BIIE 0246

BIIE 0246 is a non-peptide, competitive antagonist with high selectivity for Y2R over other NPY receptor subtypes. By binding to Y2R, BIIE 0246 blocks NPY and PYY3-36 induced presynaptic inhibition of neurotransmitter release. In hippocampal slices, BIIE 0246 abolishes NPY-induced suppression of primary afterdischarge and population excitatory postsynaptic potentials. In gastrointestinal smooth muscle, it reverses Y2R-mediated contraction. The compound does not significantly interact with Y1R, Y5R, or other related receptors at experimental concentrations (APExBIO). Pharmacologically, BIIE 0246 provides a tool for causal inference in central nervous system receptor antagonist studies and for mapping the presynaptic inhibitory effect blockade in neural pathways (see mechanistic mapping review—here, we clarify dose-response benchmarks and translational workflow details).

Evidence & Benchmarks

• BIIE 0246 exhibits an IC₅₀ of 3.3 nM and Ki of 8–15 nM for inhibition of [¹²⁵I]PYY3-36 binding to rat Y2R in membrane preparations, under physiological pH and 4°C conditions (APExBIO).
• In hippocampal slice electrophysiology, BIIE 0246 (0.1–1 μM) abolishes NPY-induced inhibition of primary afterdischarge and population excitatory postsynaptic potentials (pH 7.4, 32°C, in ACSF) (Fan et al. 2024).
• In rat colon tissue assays, BIIE 0246 (1 μM) fully prevents PYY3-36-induced smooth muscle contraction in Krebs buffer at 37°C (APExBIO).
• In behavioral models, intraperitoneal BIIE 0246 (1 mg/kg) attenuates PYY3-36-induced reduction in feeding and reduces anxiety-like behavior in the elevated plus-maze paradigm (rodent, 22°C, 12h light/dark cycle) (Fan et al. 2024).
• BIIE 0246 is stable as a white solid at 4°C and soluble up to 67.2 mg/ml in DMSO and 23.55 mg/ml in ethanol; long-term storage of solutions is not recommended (APExBIO).

Applications, Limits & Misconceptions

BIIE 0246 is validated for mechanistic studies of the NPY Y2 signaling pathway in the central nervous system and peripheral tissues. It enables precise interrogation of post-prandial satiety, feeding behavior modulation, and anxiety-related circuits. The compound is also used in models of the adipose-neural axis, contributing to the study of neurocardiac regulation and arrhythmogenesis (see translational perspective—this article updates compound stability and benchmark data). For advanced mapping of presynaptic inhibitory effect blockade, BIIE 0246 provides superior selectivity compared to peptide antagonists (contrast with prior review on neurocardiac signaling—here, we supply quantitative affinity and behavioral assay data).

Common Pitfalls or Misconceptions

1. BIIE 0246 does not antagonize Y1R, Y5R, or other NPY receptors at standard concentrations—off-target effects are minimal in validated systems.
2. It is not intended for diagnostic or therapeutic use; use is strictly for scientific research applications as specified by APExBIO.
3. Solutions are not stable for long-term storage; prepare fresh aliquots for each experiment to ensure reproducibility.
4. Behavioral effects are context-dependent; anxiolytic-like actions are validated only in specific rodent paradigms (e.g., elevated plus-maze).
5. Affinity and efficacy may vary by assay buffer, temperature, and species; always reference quantitative benchmarks for your specific system.

Workflow Integration & Parameters

BIIE 0246 (B6836) is supplied by APExBIO as a white solid, molecular weight 896.06, and chemical formula C₄₉H₅₇N₁₁O₆. It is soluble to 67.2 mg/ml in DMSO and 23.55 mg/ml in ethanol. Recommended storage: 4°C (solid); avoid repeated freeze-thaw cycles. Prepare working solutions fresh, avoiding long-term storage of aliquots. For in vitro studies, typical working concentrations are 10–1000 nM in physiological buffers. For in vivo rodent studies, dosing regimens of 0.1–1 mg/kg i.p. are common but should be optimized for species and endpoint. Refer to the product page for up-to-date handling and safety data.

Conclusion & Outlook

BIIE 0246 is a validated, high-affinity, and selective neuropeptide Y Y2 receptor antagonist for neuroscience, metabolic, and neurocardiac research. Its robust pharmacological profile underpins reproducible mechanistic studies of presynaptic inhibition, feeding behavior, and the adipose-neural axis. Ongoing research continues to extend its applications in arrhythmia and neuropsychiatric disease models. For authoritative compound supply and technical support, consult APExBIO. For further context on translational strategies, see the roadmap article—this dossier provides updated benchmarks and workflow guidance for precision research.